TICKERNERD
Menu
VTGNVTGNHealthcare · Biotechnology

VTGN Stock Forecast: Vistagen Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 13 Nov 2026
$0.18
+0.17% on the day

The 4 Wall Street analysts covering Vistagen Therapeutics, Inc. hold a median 12-month price target of $1 — +454.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 13 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$8.0M
Ticker Nerd rank
29/ 100
Median analyst target
$1.00
Analysts covering
4
Revenue$1.5M+504.9% y/y
Operating income−$13.3M
Net income−$13.0M
Free cash flow−$14.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+12.7%
1M
−14.1%
YTD
−72.7%
1Y
−95.3%
From 52W high
−96.3%
From 52W low
+12.7%
$0.16
$4.90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VTGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vistagen Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Nov 2026
29/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
92
Accruals
79
Revisions
62
Issuance
48
Volatility
44
Momentum
18
Quality
17
Growth
8
Value
8

Size (92): Smaller than most of the companies we track.

Value (8): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VTGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VTGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26VTGNHigh $1.00Median $1.00Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
0 Buy4 Hold0 Sell
Low $1.00Median $1.00High $1.00

The green dot is the last close — the median target sits +454.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Dec 2025JefferiesDowngradeHold$15 → $0.90
17 Dec 2025Maxim GroupDowngradeHold—
17 Dec 2025William BlairDowngradeMarket Perform—
7 Dec 2023JefferiesUpgradeBuy—
14 Nov 2023StifelInitiatesBuy—
5 Sept 2023Maxim GroupMaintainsBuy—
7 Aug 2023Maxim GroupUpgradeBuy—
26 July 2022Maxim GroupDowngradeHold—
22 July 2022William BlairDowngradeMarket Perform—
20 May 2021BairdInitiatesOutperform—
18 Feb 2021JefferiesInitiatesBuy—
4 Jan 2021William BlairUpgradeOutperform—
8 Oct 2020Aegis CapitalInitiatesBuy—
28 Aug 2019William BlairInitiatesOutperform—
22 July 2019Chardan CapitalDowngradeNeutral$22 → $0.70
27 June 2018Maxim GroupInitiatesBuy—
24 May 2018OppenheimerInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

VTGN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

VTGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Nov 2026, Vistagen Therapeutics, Inc. returned −95.3% against +13.4% for the S&P 500, dividends included.

VTGN vs S&P 500, last 12 monthsTotal return, rebased to 100
050100Jan 26Apr 26Jul 26Oct 26VTGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VTGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Vistagen Therapeutics, Inc. (VTGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 78% of US stocks

Price / sales
3.2×

Cheaper than 37% of US stocks

Price / book
0.3×

Cheaper than 86% of US stocks

EV / EBITDA
0.3×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
504.9%

Higher than 98% of US stocks

Earnings growth (YoY)
504.9%

Higher than 95% of US stocks

Gross margin
—
Operating margin
−2785.7%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−166.5%

Higher than 9% of US stocks

Return on assets
−83.2%

Higher than 4% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vistagen Therapeutics, Inc. (VTGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vistagen Therapeutics, Inc. has a market value of $8.0M and an enterprise value of −$23.0M.

  • Revenue in the twelve months to 30 June 2026: $2.5M. The latest quarter grew 504.9% year on year.

  • Net income over the same four quarters: −$67.6M, a −2702.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$62.4M.

  • Shares outstanding: 44.4M.

  • Trailing P/E: −0.1×; forward P/E: −0.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Vistagen Therapeutics, Inc. employs 41 people — $61K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Nov 2026

Data provided by Twelve Data

Peers

VTGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VTGNVistagen Therapeutics, Inc.$8.0M29
LGVNLongeveron, Inc.$7.9M48
ENSCEnsysce Biosciences, Inc.$8.1M34
CALCCalciMedica, Inc.$8.3M37
MBRXMoleculin Biotech, Inc.$8.3M21
GTBPGT Biopharma, Inc.$7.7M14
TPSTTempest Therapeutics, Inc.$7.6M49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vistagen Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VTGN news & analysis

Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update

GlobeNewsWire · 13 Nov 2026positive

Vistagen reported fiscal year 2027 second-quarter financial results and provided a corporate update. The update described potential advancement of a Phase 3 development plan for fasedienol in social anxiety disorder following constructive FDA feedback, alongside disciplined capital management and strategic flexibility.

Why it matters — VTGN watchers may follow the FDA feedback and potential Phase 3 plans for fasedienol, as well as the company’s approach to capital management.

Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder

GlobeNewsWire · 9 Nov 2026positive

Vistagen reported a productive Type C meeting with the U.S. FDA and said the agency’s constructive feedback clarifies a potential Phase 3 development path for fasedienol in social anxiety disorder.

Why it matters — The FDA feedback may inform the next steps in Vistagen’s planned Phase 3 development of fasedienol.

Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs

GlobeNewsWire · 20 Oct 2026positive

Vistagen selected GATC Health to apply predictive AI across its lead clinical-stage drug development programs. The collaboration will combine Vistagen’s neuroscience expertise and datasets with GATC Health’s predictive modeling capabilities.

Why it matters — The work is intended to provide additional insights for clinical protocol development and resource allocation across VTGN’s lead programs.

2 Falling Stocks Call Traders Are Targeting Today

Schaeffers Research · 25 Sept 2026positive

Schaeffers Research reported that options traders are buying the dip in Vistagen Therapeutics (VTGN) as the stock trades lower, with bullish options activity drawing attention alongside Meta Platforms.

Why it matters — Bullish options activity on VTGN despite a lower share price signals that some traders are positioning for a potential rebound.

Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety Disorder

GlobeNewsWire · 24 Sept 2026positive

Vistagen presented positive exploratory research findings supporting the potential of fasedienol in very severe social anxiety disorder at Psych Congress 2026 in New Orleans. The full poster presentation is available in the Publications section of the company's website.

Why it matters — This provides early positive clinical evidence for fasedienol, one of Vistagen's key intranasal product candidates, which could be significant for investors tracking the company's pipeline progress.

FAQ

Frequently asked questions about VTGN stock

What is the VTGN stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Vistagen Therapeutics, Inc. have a median 12-month price target of $1, with estimates ranging from $1 to $1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VTGN stock a buy right now?

Of the 4 analysts covering Vistagen Therapeutics, Inc., 0 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vistagen Therapeutics, Inc. 29 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VTGN?

As at 13 Nov 2026, Vistagen Therapeutics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).

Will VTGN stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +454.6% from the last close, and Ticker Nerd's factor model ranks Vistagen Therapeutics, Inc. 29 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VTGN stock forecast for 2030?

No analyst covering Vistagen Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VTGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $1 over the next 12 months.

How has VTGN stock performed over the past year?

Vistagen Therapeutics, Inc. returned -95.3% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vistagen Therapeutics, Inc. do?

Vistagen Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on neuropsychiatric and neurological disorders.

What is the latest news on VTGN?

The most recent item we track (GlobeNewsWire, 13 Nov 2026): "Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update". Vistagen reported fiscal year 2027 second-quarter financial results and provided a corporate update. The update described potential advancement of a Phase 3 development plan for fasedienol in social anxiety disorder following constructive FDA feedback, alongside disciplined capital management and strategic flexibility.

Company

About Vistagen Therapeutics, Inc.

Vistagen Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on neuropsychiatric and neurological disorders. The company develops intranasal product candidates known as pherines, designed to act through nose-to-brain neurocircuitry and support rapid, targeted delivery within the central nervous system. Its current pipeline centers on treatments for conditions such as social anxiety disorder, major depressive disorder, and menopause-related vasomotor symptoms. Vistagen Therapeutics Inc. also pursues research and development using human neuroscience and clinical testing to advance non-systemic therapeutic approaches. Headquartered in South San Francisco, California, the company operates in the biotechnology sector and works to address unmet needs across mental health and women’s health markets.

CEO Mr. Shawn K. Singh J.D. · 41 employees · United States · https://www.vistagen.com